• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by NGM Biopharmaceuticals Inc. (Amendment)

    2/26/24 5:16:16 PM ET
    $NGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NGM alert in real time by email
    SC 13D/A 1 eh240451717_13da7-ngm.htm AMENDMENT NO. 7

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)*

     

    NGM BIOPHARMACEUTICALS, INC.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)
     
    62921N 105
    (CUSIP Number)
     

    James Evangelista

    The Column Group, LP

    1 Letterman Drive,

    Building D, Suite DM-900

    San Francisco, CA 94129

    (415) 865-2050

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    February 25, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Securities Exchange Act”) or otherwise subject to the liabilities of that section of the Securities Exchange Act but shall be subject to all other provisions of the Securities Exchange Act (however, see the Notes).

     

     

      

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 2 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    11,103,333 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    11,103,333 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,103,333 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    13.4% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG LP (as defined in Item 2(a) below). TCG GP (as defined in Item 2(a) below) is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCG GP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q and filed with the Securities and Exchange Commission on November 2, 2023 (the “Form 10-Q”).

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 3 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group GP, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    100,000 (1)

    8

    SHARED VOTING POWER

     

    11,103,333 (2)

    9

    SOLE DISPOSITIVE POWER

     

    100,000 (1)

    10

    SHARED DISPOSITIVE POWER

     

    11,103,333 (2)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,203,333 (1)(2)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    13.5% (3)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG GP. Peter Svennilson and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCG GP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) All shares are held of record by TCG LP. TCG GP is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCG GP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (3) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 4 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group II, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    2,265,758 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    2,265,758 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,265,758 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.7% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG II LP (as defined in Item 2(a) below). TCG II GP (as defined in Item 2(a) below) is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCG II GP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 5 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group II GP, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    2,265,758 (1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    2,265,758 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,265,758 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.7% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG II LP. TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCG II GP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 6 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group Management, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    OO

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    100,000 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    100,000 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    100,000 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.1% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCGM LP (as defined in Item 2(a) below). Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCGM LP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 7 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    Ponoi Capital, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    1,298,908 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    1,298,908 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,298,908 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.6% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by Ponoi LP (as defined in Item 2(a) below). Ponoi LLC (as defined in Item 2(a) below) is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of Ponoi LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 8 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    Ponoi Management, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    1,298,908 (1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    1,298,908 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,298,908 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.6% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    OO

     

     

    (1) All shares are held of record by Ponoi LP. Ponoi LLC is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of Ponoi LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 9 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    Ponoi Capital II, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    1,298,908 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    1,298,908 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,298,908 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.6% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by Ponoi II LP (as defined in Item 2(a) below). Ponoi II LLC (as defined in Item 2(a) below) is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of Ponoi II LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 10 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    Ponoi II Management, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    1,298,908 (1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    1,298,908 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,298,908 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.6% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    OO

     

     

    (1) All shares are held of record by Ponoi II LP. Ponoi II LLC is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of Ponoi II LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 11 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group III, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    858,035 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    858,035 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    858,035 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.0% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG III LP (as defined in Item 2(a) below). TCG III GP (as defined in Item 2(a) below) is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCG III GP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 12 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group III-A, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    968,990 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    968,990 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    968,990 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.2% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG III-A LP (as defined in Item 2(a) below). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCG III GP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 13 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group III GP, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    1,827,025 (1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    1,827,025 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,827,025 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.2% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) Consists of (i) 858,035 shares held of record by TCG III LP and (ii) 968,990 shares held of record by TCG III-A LP. TCG III GP is the general partner of each of TCG III LP and TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing partners of TCG III GP and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 14 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group IV, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    2,650,177 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    2,650,177 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,650,177 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.2% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG IV LP (as defined in Item 2(a) below). TCG IV GP LP (as defined in Item 2(a) below) is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC (as defined in Item 2(a) below) is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of TCG IV GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 15 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group IV-A, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    90,442 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    90,442 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    90,442 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.1% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG IV-A LP (as defined in Item 2(a) below). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of TCG IV GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 16 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group IV GP, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    2,740,619 (1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    2,740,619 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,740,619 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.3% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) Consists of (i) 2,650,177 shares held of record by TCG IV LP and (ii) 90,442 shares held of record by TCG IV-A LP. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC is the general partner of TCG IV GP LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of TCG IV GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 17 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    TCG IV GP, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    2,740,619 (1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    2,740,619 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,740,619 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.3% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    OO

     

     

    (1) Consists of (i) 2,650,177 shares held of record by TCG IV LP and (ii) 90,442 shares held of record by TCG IV-A LP. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC is the general partner of TCG IV GP LP and the ultimate general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of TCG IV GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 18 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group Opportunity III, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    949,862 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    949,862 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    949,862 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.1% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG Opportunity III LP (as defined in Item 2(a) below). TCG Opportunity III GP LP (as defined in Item 2(a) below) is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 19 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    The Column Group Opportunity III GP, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    949,862 (1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    949,862 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    949,862 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.1% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All shares are held of record by TCG Opportunity III LP. TCG Opportunity GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity GP LLC is the general partner of TCG Opportunity GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 20 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    TCG Opportunity III GP, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    949,862 (1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    949,862 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    949,862 (1)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.1% (2)

     
    14

    TYPE OF REPORTING PERSON

     

    OO

     

     

    (1) All shares are held of record by TCG Opportunity III LP. TCG Opportunity GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity GP LLC is the general partner of TCG Opportunity GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, Timothy Kutzkey and David Goeddel, a member of the Issuer’s board of directors, are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.
    (2) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 21 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    Peter Svennilson

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF, PF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Sweden

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    44,000 (1)

    8

    SHARED VOTING POWER

     

    21,684,413 (2)

    9

    SOLE DISPOSITIVE POWER

     

    44,000 (1)

    10

    SHARED DISPOSITIVE POWER

     

    21,684,413 (2)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    21,728,413 (1)(2)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    26.3% (3)

     
    14

    TYPE OF REPORTING PERSON

     

    IN

     

     

    (1) All shares are held directly by Peter Svennilson.
    (2) Peter Svennilson is a managing partner of TCG GP, TCG II GP, TCGM LP and TCG III GP, and a managing member of Ponoi LLC, Ponoi II LLC, TCG Opportunity III GP LLC and TCG IV GP LLC and may be deemed to share voting and dispositive control over the shares of Common Stock held by TCG LP, TCG GP, TCG II LP, TCGM LP, Ponoi LP, Ponoi II LP, TCG III LP, TCG III-A LP, TCG Opportunity III LP, TCG IV LP and TCG IV-A LP.
    (3) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 22 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    David V. Goeddel

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF, PF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A.

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    205,096 (1)

    8

    SHARED VOTING POWER

     

    21,874,413 (2)

    9

    SOLE DISPOSITIVE POWER

     

    205,096 (1)

    10

    SHARED DISPOSITIVE POWER

     

    21,874,413 (2)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    22,079,509 (1)(2)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    26.7% (3)

     
    14

    TYPE OF REPORTING PERSON

     

    IN

     

     

    (1) Consists of (i) 134,180 shares held directly by David Goeddel and (ii) 70,916 shares underlying stock options granted to David Goeddel for his service as a member of the Issuer’s board of directors, which vest within 60 days of this statement.
    (2) David Goeddel, a member of the Issuer’s board of directors, is a managing partner of TCG GP, TCG II GP, TCGM LP and TCG III GP, and a managing member of Ponoi LLC, Ponoi II LLC, TCG Opportunity III GP LLC and TCG IV GP LLC and may be deemed to share voting and dispositive control over the shares of Common Stock held by TCG LP, TCG GP, TCG II LP, TCGM LP, Ponoi LP, Ponoi II LP, TCG III LP, TCG III-A LP, TCG Opportunity III LP, TCG IV LP and TCG IV-A LP. David Goeddel serves as co-trustee of the David V. Goeddel and Alena Z. Goeddel 2004 Trust (the “Goeddel Trust”) and shares voting and dispositive control over 190,000 shares of Common Stock held directly by the Goeddel Trust.
    (3)

    Based on 82,786,423 shares of Common Stock outstanding, which consists of (a) 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q plus (b) 70,916 shares underlying stock options granted to David Goeddel for his service as a member of the Issuer's board of directors, which vest within 60 days of this statement.

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 23 of 28

     

     

    1

    NAME OF REPORTING PERSON

     

    Timothy Kutzkey

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    SOURCE OF FUNDS

     

    AF, PF

     
    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A.

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER

     

    15,000 (1)

    8

    SHARED VOTING POWER

     

    8,215,322 (2)

    9

    SOLE DISPOSITIVE POWER

     

    15,000 (1)

    10

    SHARED DISPOSITIVE POWER

     

    8,215,322 (2)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,230,322 (1)(2)

     
    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    9.9% (3)

     
    14

    TYPE OF REPORTING PERSON

     

    IN

     

     

    (1) All shares are held directly by Timothy Kutzkey.
    (2) Timothy Kutzkey is a managing member of Ponoi LLC, Ponoi II LLC, TCG Opportunity III GP LLC and TCG IV GP LLC, and a managing partner of TCG III GP and TCGM LP and may be deemed to share voting and dispositive control over the shares of Common Stock held by Ponoi LP, Ponoi II LP, TCG III LP, TCG III-A LP, TCG Opportunity III LP, TCG IV LP, TCG IV-A LP and TCGM LP.
    (3) Based on 82,715,507 shares of Common Stock outstanding as of October 30, 2023, as reported in the Form 10-Q. 

     

     

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 24 of 28

     

     

    Item 1. Security and Issuer

    This Amendment No. 7 supplements and amends the Schedule 13D relating to shares of common stock, par value $0.001 per share (the “Common Stock”), of NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Issuer”), that was filed with the Securities and Exchange Commission (the “SEC”) on April 12, 2019 as it has been amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5 and Amendment No. 6 that were filed with the SEC on May 17, 2019, October 18, 2019, April 2, 2020, February 3, 2022, June 10, 2022 and December 29, 2023, respectively (collectively, the “Amended Statement”). Only those items that are reported are hereby amended; all other items reported in the Amended Statement remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Amended Statement. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.

    Item 3. Source and Amount of Funds or Other Consideration

    The information set forth in Item 4 hereof is hereby incorporated by reference into this Item 3, as applicable.

    Item 4. Purpose of Transaction

    Item 4 of the Amended Statement is hereby amended and supplemented by adding the following:

    Agreement and Plan of Merger

    On February 25, 2024, the Issuer entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Atlas Neon Parent, Inc., a Delaware corporation (“Parent”), and Atlas Neon Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”). Parent and Merger Sub are affiliates of the Reporting Persons.

    The Merger Agreement provides for, among other things, (i) the acquisition of the Issuer by Parent through a cash tender offer (the “Offer”) by Merger Sub for the Issuer’s outstanding shares of Common Stock for $1.55 per share (the “Offer Price”) and (ii) the merger of Merger Sub with and into the Issuer (the “Merger”) with the Issuer surviving the Merger. Subject to the terms of the Merger Agreement, the Offer Price will be paid subject to any applicable tax withholding and without interest.

    Upon the unanimous recommendation of a Special Committee (the “Special Committee”) of the Issuer’s Board of Directors (the “Board”), the members of the Board (other than Messrs. Goeddel and Perlmutter, who recused themselves because of their relationship to the Reporting Persons, and Mr. Rieflin, who recused himself because he is party to the Stockholder Rollover Agreement (as defined below)) have unanimously determined that the terms of the Offer, the Merger and the other transactions contemplated by the Merger Agreement are fair to and in the best interests of the Issuer and its stockholders other than the Reporting Persons, Parent, Merger Sub, the Rollover Stockholders (as defined below), the members of the Board and the officers of the Issuer subject to Section 16 of the Exchange Act (the “Unaffiliated Stockholders”), authorized and approved the execution, delivery and performance by the Issuer of the Merger Agreement and, subject to the terms and conditions of the Merger Agreement, the consummation by the Issuer of the transactions contemplated by the Merger Agreement, declared the Merger Agreement and the transactions contemplated by the Merger Agreement advisable and recommended that the Unaffiliated Stockholders accept the Offer and tender their shares of Common Stock pursuant to the Offer. Under the Merger Agreement, Parent is required to commence the Offer no later than 10 business days after the date of the Merger Agreement. The Offer will expire at one minute after 11:59 p.m., Eastern time, on the 20th business day of the Offer, unless extended in accordance with the terms of the Offer and the Merger Agreement and the applicable rules and regulations of the SEC.

    Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger (the “Effective Time”), by virtue of the Merger and without any action on the part of the holders, (i) each outstanding share of Common Stock of the Issuer (other than any shares of Common Stock (a) held in the treasury of the Issuer, (b) owned, directly or indirectly, by the Reporting Persons, Parent, Merger Sub, any other subsidiary of Parent, or the Rollover

     

      

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 25 of 28

     

     

    Stockholders at the commencement of the Offer and immediately prior to the Effective Time (other than those otherwise tendered in the Offer by such stockholders), (c) irrevocably accepted for purchase in the Offer or (d) owned by any stockholders who are entitled to and who properly exercise appraisal rights under Delaware law) will be converted into the right to receive the Offer Price without interest, less any applicable tax withholding; (ii) the vesting of each option to purchase shares of Common Stock from the Issuer (“Company Stock Options”) shall be accelerated and (A) each Company Stock Option that has an exercise price per share that is less than the Offer Price (each, an “In-the-Money Option”) that is then outstanding will be cancelled and, in exchange therefor, the holder of such cancelled In-the-Money Option will be entitled to receive an amount in cash, without any interest thereon and subject to applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such In-the-Money Option as of immediately prior to the Effective Time multiplied by (y) the excess of the Offer Price over the applicable exercise price per share of Common Stock underlying such In-the-Money Option, and (B) each Company Stock Option that is not an In-the-Money Option will be cancelled for no consideration; and (iii) each unvested restricted stock unit (“RSU”) of the Issuer that is then outstanding shall become immediately vested in full and cancelled, and, in exchange therefor, the holder of such cancelled RSU will be entitled to receive an amount in cash without interest, less any applicable tax withholding, equal to the Offer Price.

    Merger Sub’s obligation to accept shares of Common Stock tendered in the Offer is subject to conditions, including: (i) that the number of shares of Common Stock validly tendered and not validly withdrawn, equals at least a majority of all shares of Common Stock then owned by the Unaffiliated Stockholders as of the expiration of the Offer; (ii) the accuracy of the Issuer’s representations and warranties contained in the Merger Agreement (subject to certain exceptions and qualifications described in the Merger Agreement and except, generally, for any inaccuracies that have not had a Company Material Adverse Effect (as defined in the Merger Agreement)), (iii) the Issuer’s performance in all material respects of its obligations under the Merger Agreement and (iv) the other conditions set forth in Exhibit A to the Merger Agreement. The obligations of Parent and Merger Sub to consummate the Offer and the Merger under the Merger Agreement are not subject to a financing condition.

    Following the completion of the Offer, subject to the absence of injunctions or other legal restraints preventing or prohibiting the consummation of the Merger, Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent, pursuant to the procedure provided for under Section 251(h) of the Delaware General Corporation Law, without any additional stockholder approvals. The Merger will be effected as soon as practicable following the time at which Merger Sub purchases the shares of Common Stock validly tendered and not withdrawn in the Offer.

    The Merger Agreement contains customary representations and warranties by Parent, Merger Sub and the Issuer. The Merger Agreement also contains customary covenants and agreements, including with respect to the operations of the business of the Issuer between signing and closing.

    The Merger Agreement contains customary non-solicitation restrictions prohibiting the Issuer’s solicitation of alternative business combination transactions and restricts the Issuer’s ability to furnish non-public information to, or participate in any discussions or negotiations with, any third party with respect to any such alternative business combination transaction, subject to customary exceptions in the event of an acquisition proposal that was not solicited in violation of these restrictions and that the Board (acting upon the recommendation of the Special Committee) or the Special Committee determines constitutes or could reasonably be expected to lead to a Superior Company Proposal (as defined in the Merger Agreement).

    The Merger Agreement contains customary termination rights for both Parent and Merger Sub, on the one hand, and the Issuer, on the other hand, including, among others, for failure to consummate the Offer on or before June 15, 2024. If the Merger Agreement is terminated under certain circumstances specified in the Merger Agreement in connection with the Issuer’s entry into an agreement with respect to a Superior Company Proposal, the Issuer will be required to pay Parent a termination fee of $2.0 million.

    The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit 1 hereto. If the Merger is effected, the Issuer’s Common Stock will be delisted from The Nasdaq Stock Market LLC and the Issuer’s obligation to file periodic reports under the Exchange Act will terminate, and the Issuer will be privately held.

     

      

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 26 of 28

     

     

    Guaranty

    Concurrently with the execution of the Merger Agreement, and as a condition and inducement to the Issuer’s willingness to enter into the Merger Agreement, The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP executed and delivered to the Issuer a limited guaranty (the “Limited Guaranty”), dated as of the date of the Merger Agreement, in favor of the Issuer, in respect of certain of Parent and the Merger Sub’s obligations arising under, or in connection with, the Merger Agreement. The obligations under the Limited Guaranty are subject to a cap of $10 million, subject to certain other terms and conditions.

    The foregoing description of the terms of the Limited Guaranty does not purport to be complete and is qualified in its entirety by reference to the complete text of the Limited Guaranty, which is filed herewith as Exhibit 2.

    Rollover Agreement

    Concurrently with the execution of the Merger Agreement, certain of the Reporting Persons entered into a rollover agreement (the “TCG Rollover Agreement”) with Parent and Merger Sub, dated as of the date of the Merger Agreement. In addition, certain of the Issuer’s other stockholders, including the Chairman of the Issuer’s board (collectively, the “Rollover Stockholders”), who in the aggregate hold approximately 22% of the Issuer’s Common Stock, have entered into a rollover agreement (the “Stockholder Rollover Agreement” and, together with the TCG Rollover Agreement, the “Rollover Agreements”) with Parent and Merger Sub, dated as of the date of the Merger Agreement. Pursuant to the applicable Rollover Agreement, the Reporting Persons party thereto and each of the Rollover Stockholders have agreed, among other things, that they will not transfer or tender their shares of Common Stock subject to the applicable Rollover Agreement in the Offer and that instead (i) such shares of Common Stock will be contributed to Parent immediately prior to the closing of the Merger, and (ii) in consideration for such contribution, Parent will issue to the Reporting Persons and each Rollover Stockholder, as applicable, common shares of Parent. Each Rollover Agreement provides that it will terminate in the event the Merger Agreement is terminated in accordance with its terms. Each Rollover Agreement contains other representations, warranties, and covenants of the parties thereto, as applicable, and other terms in connection with the shares of Common Stock subject to each Rollover Agreement and matters related to Parent prior to and following the closing.

    The foregoing description of the terms of the Rollover Agreements does not purport to be complete and is qualified in its entirety by reference to the complete text of the Rollover Agreements, which are filed herewith as Exhibit 3 and 4, respectively.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The information set forth in Item 4 hereof is hereby incorporated by reference into this Item 6, as applicable.

    Item 7. Material to be Filed as Exhibits.

    Exhibit No.   Description
    1   Agreement and Plan of Merger between the Issuer, Parent and Merger Sub, dated February 25, 2024 (incorporated by reference to Exhibit 2.1 to the Issuer’s Current Report on Form 8-K filed with the SEC on February 26, 2024)
    2   Limited Guaranty, dated February 25, 2024 (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed with the SEC on February 26, 2024)
    3   TCG Rollover Agreement, between certain of the Reporting Persons, Parent and Merger Sub, dated February 25, 2024.
    4   Stockholder Rollover Agreement, between certain stockholders, Parent and Merger Sub, dated February 25, 2024

     

     

     

      

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 27 of 28

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 26, 2024

           
    THE COLUMN GROUP, LP       THE COLUMN GROUP GP, LP  
               
    By:   The Column Group GP, LP              
               
    By:   /s/ James Evangelista, Partner & Chief Financial Officer       By:   /s/ James Evangelista, Partner & Chief Financial Officer  
           
    THE COLUMN GROUP II, LP       THE COLUMN GROUP II GP, LP  
               
    By:   The Column Group II GP, LP       By:   /s/ James Evangelista, Partner & Chief Financial Officer  
               
    By:   /s/ James Evangelista, Partner & Chief Financial Officer              
           
    PONOI CAPITAL, LP       PONOI MANAGEMENT, LLC  
               
    By:   Ponoi Management, LLC       By:   /s/ James Evangelista, Partner & Chief Financial Officer  
               
    By:   /s/ James Evangelista, Partner & Chief Financial Officer              
           
    PONOI CAPITAL II, LP       PONOI II MANAGEMENT, LLC  
               
    By:   Ponoi II Management, LLC       By:   /s/ James Evangelista, Partner & Chief Financial Officer  
               
    By:   /s/ James Evangelista, Partner & Chief Financial Officer              
           
    THE COLUMN GROUP MANAGEMENT, LP       THE COLUMN GROUP III GP, LP  
               
    By:   /s/ James Evangelista, Partner & Chief Financial Officer       By:   /s/ James Evangelista, Partner & Chief Financial Officer  
           
    THE COLUMN GROUP III, LP       THE COLUMN GROUP III-A, LP  
               
    By:  

    The Column Group III GP, LP

          By:  

    The Column Group III GP, LP

     
               
    By:   /s/ James Evangelista, Attorney-in-Fact on behalf of Timothy Kutzkey       By:   /s/ James Evangelista, Attorney-in-Fact on behalf of Timothy Kutzkey  
               
    By:   /s/ James Evangelista, Attorney-in-Fact on behalf of Peter Svennilson       By:   /s/ James Evangelista, Attorney-in-Fact on behalf of Peter Svennilson  
               
    By:   /s/ James Evangelista, Attorney-in-Fact on behalf of David V. Goeddel       By:   /s/ James Evangelista, Attorney-in-Fact on behalf of David V. Goeddel  
             
    THE COLUMN GROUP IV, LP              
               
    By:   The Column Group IV GP, LP              
               
    By:   TCG IV GP, LLC              
                       
    By:   /s/ James Evangelista, Partner & Chief Financial Officer              

     

     

      

     

     

    CUSIP No. 62921N 105 SCHEDULE 13D Page 28 of 28

     

     

    THE COLUMN GROUP IV-A, LP  
         
    By:   The Column Group IV GP, LP  
         
    By:   TCG IV GP, LLC  
         
    By:   /s/ James Evangelista, Partner & Chief Financial Officer  
       
    THE COLUMN GROUP IV GP, LP  
         
    By:   TCG IV GP, LLC  
         
    By:   /s/ James Evangelista, Partner & Chief Financial Officer  
       
    TCG IV GP, LLC  
         
    By:   /s/ James Evangelista, Partner & Chief Financial Officer  

     

    THE COLUMN GROUP OPPORTUNITY III, LP

     
         
    By:   The Column Group Opportunity III GP, LP  
         
    By:  

    TCG Opportunity III GP, LLC

     
         
    By:   /s/ James Evangelista, Partner & Chief Financial Officer  
       
    THE COLUMN GROUP OPPORTUNITY III GP, LP  
         
    By:  

    TCG Opportunity III GP, LLC

     
         
    By:   /s/ James Evangelista, Partner & Chief Financial Officer  
       
    TCG OPPORTUNITY III GP, LLC  
         
    By:   /s/ James Evangelista, Partner & Chief Financial Officer  
     
    TIMOTHY KUTZKEY  
         
    By:  

    /s/ James Evangelista, Attorney-in-Fact

     
     
    PETER SVENNILSON  
         
    By:  

    /s/ James Evangelista, Attorney-in-Fact

     
     
    DAVID V. GOEDDEL  
         
    By:  

    /s/ James Evangelista, Attorney-in-Fact

     

     

     

     

     

    Get the next $NGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NGM

    DatePrice TargetRatingAnalyst
    3/12/2024Outperform → Mkt Perform
    Raymond James
    2/28/2024Outperform → Market Perform
    TD Cowen
    2/27/2024Buy → Neutral
    Citigroup
    5/3/2023$6.00Buy
    Citigroup
    10/18/2022$29.00 → $4.00Buy → Neutral
    Goldman
    10/18/2022$42.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/17/2022Buy → Hold
    Jefferies
    10/17/2022Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $NGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NGM Bio Announces Closing of Tender Offer

      SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. ("Parent"), an affiliate of The Column Group, LP ("TCG"), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. ("Merger Sub"), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain other stockholders at a price per share of $1.55 in cash (the "Offer Price"). The tender offer and related withdrawal rights expired at one minute a

      4/5/24 9:19:51 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

      SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA. Poster Presentation Details: Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose esca

      3/19/24 5:30:44 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

      --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravidarum (HG) by the end of 2024-- --Ongoing discussions with regulators on the design of a potential registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of primary sclerosing chola

      3/11/24 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:33:24 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:30:19 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:28:01 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    SEC Filings

    See more
    • SEC Form 15-12G filed by NGM Biopharmaceuticals Inc.

      15-12G - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)

      4/15/24 7:57:22 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NGM Biopharmaceuticals Inc.

      EFFECT - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)

      4/9/24 12:15:15 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by NGM Biopharmaceuticals Inc.

      25-NSE - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      4/5/24 11:22:54 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NGM Biopharmaceuticals downgraded by Raymond James

      Raymond James downgraded NGM Biopharmaceuticals from Outperform to Mkt Perform

      3/12/24 7:29:29 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Biopharmaceuticals downgraded by TD Cowen

      TD Cowen downgraded NGM Biopharmaceuticals from Outperform to Market Perform

      2/28/24 6:43:03 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Biopharmaceuticals downgraded by Citigroup

      Citigroup downgraded NGM Biopharmaceuticals from Buy to Neutral

      2/27/24 8:54:39 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tcg Opportunity Iii Gp, Llc returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:05:48 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group Gp, Lp returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:04:43 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:03:30 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Leadership Updates

    Live Leadership Updates

    See more
    • NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data

      Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product candidate, compared to patients treated with placeboInitiated the first two Phase 2b expansion cohorts in the Phase 1/2 trial evaluating NGM707, an ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab)Announced the appointment of Dan Kaplan, Ph.D. to Chief Scientific OfficerExtended expected cash runway into the second quarter of 2025 following a restructuring o

      5/4/23 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marathon Health Expands Board of Directors

      INDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ -- Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced primary care model.  Ms. Obi Felton, Ms. Siobhan Nolan Mangini, Dr. Glenn Steele and Mr. Bill Whitely bring a strong and diverse set of track records and experience, spanning leadership in clinical quality, patient experience, technology, and rapid growth. Marathon's appointment of these four Directors comes at an exciting inflecti

      2/8/22 7:00:00 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results

      Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022Initiated a Phase 1/2 clinical trial of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumorsAmended collaboration with Merck to focus primarily on advancing novel medicines for retinal and cardiovascular and metabolic diseases; NGM gained worldwide rights to its disclosed oncology portfolio as well as additional assets falling outside of the amended collaboration's narrower scope$390.6 million in cash, cash equivalents and marketable securities as of June 30, 2021 SOUTH SAN

      8/5/21 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Financials

    Live finance-specific insights

    See more
    • NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

      Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus shamNGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEsAdditional analyses to be presented in early November at The Retina Society Annual Scientific MeetingNGM Bio to host conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced topline efficacy

      10/17/22 7:30:00 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

      SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration. To access the live webcast and slides, please visit the "Investors & Media" section of NGM Bio's website at https://ir.ngmbio.com/. The webcast will be archived for 30 days. About NGM Bio NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives ha

      10/16/22 4:30:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      4/5/24 10:55:55 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      2/26/24 5:16:16 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13G/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      2/14/24 6:12:53 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care